Abstract
Cilostazol, a specific type-III phosphodiesterase inhibitor, is widely used for the treatment of ischemic symptoms of peripheral vascular disease. Recent studies have reported that the mechanism of cilostazol is related to the suppression of pro-inflammatory cytokine production and improvement of local microcirculation disturbances. The pathogenesis of stress-induced gastric mucosal lesions is characterized by the activation of inflammatory cells and the production of inflammatory cytokines. The effects of cilostazol on the development of gastric mucosal lesions have not been reported. In the present study, we examined the effect of a cilostazol on water-immersion stress-induced gastric mucosal lesions. Rats were subjected to water-immersion stress with or without pretreatment with a single intraperitoneal injection of the selective type-III phosphodiesterase inhibitor, cilostazol. We measured the gastric mucosal lesion and the concentrations of myeloperoxidase (MPO), interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and cytokine-induced neutrophil chemoattractant-1 (GRO/CINC-1), as an index of neutrophil accumulation and pro-inflammatory cytokine production. Cilostazol ameliorated the gastric mucosal injur...Continue Reading
References
May 7, 1976·Analytical Biochemistry·M M Bradford
Nov 1, 1992·International Journal of Immunopharmacology·T YoshikawaM Kondo
Mar 1, 1982·The Journal of Investigative Dermatology·P P BradleyG Rothstein
Sep 1, 1995·Clinical and Experimental Immunology·A R Moore, D A Willoughby
Feb 1, 1993·The Journal of Clinical Investigation·M S MulliganP A Ward
Jan 1, 1994·Journal of Applied Physiology·B N Cronstein
Dec 1, 1996·Alimentary Pharmacology & Therapeutics·Y HisanagaS Sugiyama
Jun 26, 1998·Journal of Gastroenterology and Hepatology·H SuzukiH Ishii
Feb 10, 2000·Circulation Research·S KokuraT Y Aw
May 5, 2000·Digestive Diseases and Sciences·T WatanabeT Kuroki
May 1, 2001·Alimentary Pharmacology & Therapeutics·H SuzukiH Ishii
Nov 1, 2001·Journal of Gastroenterology and Hepatology·I I BlandinoS Watanabe
Jan 5, 2002·Digestive Diseases and Sciences·M HamaguchiT Arakawa
Jan 24, 2002·The Journal of Pharmacology and Experimental Therapeutics·Ki Young KimKi Whan Hong
Feb 7, 2002·Cardiovascular Drug Reviews·Y LiuJ Kambayashi Ji
Oct 8, 2003·Current Pharmaceutical Design·Junichi KambayashiFrank Czerwiec
Feb 18, 2004·Circulation·Hwa Kyoung ShinKi Whan Hong
Jun 1, 2004·Respiratory Research·Robert A ClaytonSimon J MacKenzie
Aug 18, 2004·Microvascular Research·Hitoshi OmiMakoto Itoh
Feb 3, 2005·Journal of Gastroenterology and Hepatology·Masaru OdashimaSumio Watanabe
Citations
Nov 7, 2013·BMC Complementary and Alternative Medicine·Mohan KumarRaj Kumar Goel
Oct 17, 2007·Journal of Atherosclerosis and Thrombosis·Daisuke MoriMasayuki Yoshida
Jul 2, 2014·Life Sciences·Koji TakeuchiChitose Izuhara
Jun 20, 2014·Journal of Atherosclerosis and Thrombosis·Yongwhi ParkYoung-Hoon Jeong
Mar 21, 2007·Digestive Diseases and Sciences·Masaru OdashimaSumio Watanabe
Feb 4, 2014·Annals of Vascular Surgery·Tunay KurtogluBerent Discigil
Feb 24, 2009·Life Sciences·Juliana Barros MendesSilvia Passos Andrade
Oct 10, 2009·American Journal of Physiology. Gastrointestinal and Liver Physiology·Hisayuki MatsunagaSoichiro Miura
Sep 1, 2012·Scandinavian Journal of Gastroenterology·Masaaki HigashiyamaSoichiro Miura
Dec 4, 2014·Marine Drugs·Jing-Yi HouYuan-Lu Cui
May 20, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Asmaa Mohamed Abdel-AzizSeham A Abdel-Gaber
Oct 16, 2012·Scandinavian Journal of Gastroenterology·Shailendra Kapoor
Aug 3, 2019·Naunyn-Schmiedeberg's Archives of Pharmacology·Helmy MoawadMohammed A Alkhawlani
Sep 21, 2020·European Journal of Pharmacology·Pegah DejbanAhmad Reza Dehpour